L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.
Identifieur interne : 000608 ( Hal/Corpus ); précédent : 000607; suivant : 000609L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.
Auteurs : Sylvia Navailles ; Manolo Carta ; Martin Guthrie ; Philippe De DeurwaerdèreSource :
- Central Nervous System Agents in Medicinal Chemistry [ 1871-5249 ] ; 2011-12-01.
Abstract
L-DOPA is the gold standard medication of Parkinson's disease, a neurological disorder consequent upon the degeneration of mesencephalic dopaminergic neurons. The therapeutic efficacy of L-DOPA has been related to its ability to restore dopamine (DA) extracellular levels in the Parkinsonian brain. The origin of the L-DOPA-induced rise in DA has been the object of numerous studies and controversies but the data collectively point to serotonergic (5-HT) neurons as being most significant in the release. Here, we review biochemical and behavioral evidence supporting serotonergic neurons as playing the main role in the actions of L-DOPA, considered from two points of view. The main aspect concerns the biochemical demonstration that 5-HT neurons are almost solely implicated in the release of DA induced by L-DOPA. The mechanism of action of L-DOPA inside 5-HT neurons will be thoroughly dissected on the basis of L-DOPA effects on extracellular versus tissue DA levels. The unique contribution of 5-HT neurons in mediating the release of newly synthesised DA from L-DOPA will be discussed in parallel with DA-dependent behaviors induced by L-DOPA. The other, and neglected, aspect concerns the possible deleterious impact of the presence of L-DOPA inside 5-HT neurons on 5-HT neuronal function. Overall, the fact that 5-HT neurons release the newly synthesised DA from L-DOPA in multiple brain regions beyond the striatum gives new insight into the large impact of L-DOPA in the Parkinsonian brain and strengthens therapeutic perspectives targeting the 5-HT system to reduce both motor and non-motor complications of L-DOPA medication.
Url:
Links to Exploration step
Hal:hal-01178542Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.</title>
<author><name sortKey="Navailles, Sylvia" sort="Navailles, Sylvia" uniqKey="Navailles S" first="Sylvia" last="Navailles">Sylvia Navailles</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID"> <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
<orgName type="acronym">IMN</orgName>
<desc> <address> <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://imn-bordeaux.org/</ref>
</desc>
<listRelation> <relation active="#struct-259761" type="direct"></relation>
<relation name="UMR5293" active="#struct-441569" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName>
<orgName type="acronym">UB</orgName>
<desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-bordeaux.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"> <idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc> <address> <country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name>
</author>
<author><name sortKey="Guthrie, Martin" sort="Guthrie, Martin" uniqKey="Guthrie M" first="Martin" last="Guthrie">Martin Guthrie</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID"> <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
<orgName type="acronym">IMN</orgName>
<desc> <address> <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://imn-bordeaux.org/</ref>
</desc>
<listRelation> <relation active="#struct-259761" type="direct"></relation>
<relation name="UMR5293" active="#struct-441569" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName>
<orgName type="acronym">UB</orgName>
<desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-bordeaux.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"> <idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc> <address> <country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdère">Philippe De Deurwaerdère</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID"> <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
<orgName type="acronym">IMN</orgName>
<desc> <address> <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://imn-bordeaux.org/</ref>
</desc>
<listRelation> <relation active="#struct-259761" type="direct"></relation>
<relation name="UMR5293" active="#struct-441569" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName>
<orgName type="acronym">UB</orgName>
<desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-bordeaux.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"> <idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc> <address> <country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-01178542</idno>
<idno type="halId">hal-01178542</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-01178542</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-01178542</idno>
<date when="2011-12-01">2011-12-01</date>
<idno type="wicri:Area/Hal/Corpus">000608</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.</title>
<author><name sortKey="Navailles, Sylvia" sort="Navailles, Sylvia" uniqKey="Navailles S" first="Sylvia" last="Navailles">Sylvia Navailles</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID"> <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
<orgName type="acronym">IMN</orgName>
<desc> <address> <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://imn-bordeaux.org/</ref>
</desc>
<listRelation> <relation active="#struct-259761" type="direct"></relation>
<relation name="UMR5293" active="#struct-441569" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName>
<orgName type="acronym">UB</orgName>
<desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-bordeaux.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"> <idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc> <address> <country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name>
</author>
<author><name sortKey="Guthrie, Martin" sort="Guthrie, Martin" uniqKey="Guthrie M" first="Martin" last="Guthrie">Martin Guthrie</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID"> <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
<orgName type="acronym">IMN</orgName>
<desc> <address> <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://imn-bordeaux.org/</ref>
</desc>
<listRelation> <relation active="#struct-259761" type="direct"></relation>
<relation name="UMR5293" active="#struct-441569" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName>
<orgName type="acronym">UB</orgName>
<desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-bordeaux.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"> <idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc> <address> <country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdère">Philippe De Deurwaerdère</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID"> <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
<orgName type="acronym">IMN</orgName>
<desc> <address> <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://imn-bordeaux.org/</ref>
</desc>
<listRelation> <relation active="#struct-259761" type="direct"></relation>
<relation name="UMR5293" active="#struct-441569" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName>
<orgName type="acronym">UB</orgName>
<desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-bordeaux.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"> <idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc> <address> <country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Central Nervous System Agents in Medicinal Chemistry</title>
<idno type="ISSN">1871-5249</idno>
<imprint><date type="datePub">2011-12-01</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">L-DOPA is the gold standard medication of Parkinson's disease, a neurological disorder consequent upon the degeneration of mesencephalic dopaminergic neurons. The therapeutic efficacy of L-DOPA has been related to its ability to restore dopamine (DA) extracellular levels in the Parkinsonian brain. The origin of the L-DOPA-induced rise in DA has been the object of numerous studies and controversies but the data collectively point to serotonergic (5-HT) neurons as being most significant in the release. Here, we review biochemical and behavioral evidence supporting serotonergic neurons as playing the main role in the actions of L-DOPA, considered from two points of view. The main aspect concerns the biochemical demonstration that 5-HT neurons are almost solely implicated in the release of DA induced by L-DOPA. The mechanism of action of L-DOPA inside 5-HT neurons will be thoroughly dissected on the basis of L-DOPA effects on extracellular versus tissue DA levels. The unique contribution of 5-HT neurons in mediating the release of newly synthesised DA from L-DOPA will be discussed in parallel with DA-dependent behaviors induced by L-DOPA. The other, and neglected, aspect concerns the possible deleterious impact of the presence of L-DOPA inside 5-HT neurons on 5-HT neuronal function. Overall, the fact that 5-HT neurons release the newly synthesised DA from L-DOPA in multiple brain regions beyond the striatum gives new insight into the large impact of L-DOPA in the Parkinsonian brain and strengthens therapeutic perspectives targeting the 5-HT system to reduce both motor and non-motor complications of L-DOPA medication.</div>
</front>
</TEI>
<hal api="V3"> <titleStmt> <title xml:lang="en">L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.</title>
<author role="aut"> <persName> <forename type="first">Sylvia</forename>
<surname>Navailles</surname>
</persName>
<idno type="halauthorid">1167834</idno>
<affiliation ref="#struct-244085"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Manolo</forename>
<surname>Carta</surname>
</persName>
<idno type="halauthorid">1190816</idno>
</author>
<author role="aut"> <persName> <forename type="first">Martin</forename>
<surname>Guthrie</surname>
</persName>
<idno type="halauthorid">858146</idno>
<affiliation ref="#struct-244085"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Philippe</forename>
<surname>De Deurwaerdère</surname>
</persName>
<idno type="halauthorid">1169525</idno>
<affiliation ref="#struct-244085"></affiliation>
</author>
<editor role="depositor"> <persName> <forename>Philippe</forename>
<surname>De Deurwaerdere</surname>
</persName>
<email type="md5">ea9841169841792cc22b5da7df57965f</email>
<email type="domain">u-bordeaux.fr</email>
</editor>
</titleStmt>
<editionStmt> <edition n="v1" type="current"> <date type="whenSubmitted">2015-07-20 13:16:26</date>
<date type="whenModified">2015-07-21 01:00:17</date>
<date type="whenReleased">2015-07-20 13:16:26</date>
<date type="whenProduced">2011-12-01</date>
</edition>
<respStmt> <resp>contributor</resp>
<name key="318954"> <persName> <forename>Philippe</forename>
<surname>De Deurwaerdere</surname>
</persName>
<email type="md5">ea9841169841792cc22b5da7df57965f</email>
<email type="domain">u-bordeaux.fr</email>
</name>
</respStmt>
</editionStmt>
<publicationStmt> <distributor>CCSD</distributor>
<idno type="halId">hal-01178542</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-01178542</idno>
<idno type="halBibtex">navailles:hal-01178542</idno>
<idno type="halRefHtml">Central Nervous System Agents in Medicinal Chemistry, Bentham Science Publishers, 2011, 11 (4), pp.305-20</idno>
<idno type="halRef">Central Nervous System Agents in Medicinal Chemistry, Bentham Science Publishers, 2011, 11 (4), pp.305-20</idno>
</publicationStmt>
<seriesStmt> <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
</seriesStmt>
<notesStmt> <note type="audience" n="2">International</note>
<note type="popular" n="0">No</note>
<note type="peer" n="1">Yes</note>
</notesStmt>
<sourceDesc> <biblStruct> <analytic> <title xml:lang="en">L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.</title>
<author role="aut"> <persName> <forename type="first">Sylvia</forename>
<surname>Navailles</surname>
</persName>
<idno type="halauthorid">1167834</idno>
<affiliation ref="#struct-244085"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Manolo</forename>
<surname>Carta</surname>
</persName>
<idno type="halauthorid">1190816</idno>
</author>
<author role="aut"> <persName> <forename type="first">Martin</forename>
<surname>Guthrie</surname>
</persName>
<idno type="halauthorid">858146</idno>
<affiliation ref="#struct-244085"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Philippe</forename>
<surname>De Deurwaerdère</surname>
</persName>
<idno type="halauthorid">1169525</idno>
<affiliation ref="#struct-244085"></affiliation>
</author>
</analytic>
<monogr> <idno type="halJournalId" status="VALID">38559</idno>
<idno type="issn">1871-5249</idno>
<title level="j">Central Nervous System Agents in Medicinal Chemistry</title>
<imprint> <publisher>Bentham Science Publishers</publisher>
<biblScope unit="volume">11</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="pp">305-20</biblScope>
<date type="datePub">2011-12-01</date>
</imprint>
</monogr>
<idno type="pubmed">22117594</idno>
</biblStruct>
</sourceDesc>
<profileDesc> <langUsage> <language ident="en">English</language>
</langUsage>
<textClass> <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
<classCode scheme="halTypology" n="ART">Journal articles</classCode>
</textClass>
<abstract xml:lang="en">L-DOPA is the gold standard medication of Parkinson's disease, a neurological disorder consequent upon the degeneration of mesencephalic dopaminergic neurons. The therapeutic efficacy of L-DOPA has been related to its ability to restore dopamine (DA) extracellular levels in the Parkinsonian brain. The origin of the L-DOPA-induced rise in DA has been the object of numerous studies and controversies but the data collectively point to serotonergic (5-HT) neurons as being most significant in the release. Here, we review biochemical and behavioral evidence supporting serotonergic neurons as playing the main role in the actions of L-DOPA, considered from two points of view. The main aspect concerns the biochemical demonstration that 5-HT neurons are almost solely implicated in the release of DA induced by L-DOPA. The mechanism of action of L-DOPA inside 5-HT neurons will be thoroughly dissected on the basis of L-DOPA effects on extracellular versus tissue DA levels. The unique contribution of 5-HT neurons in mediating the release of newly synthesised DA from L-DOPA will be discussed in parallel with DA-dependent behaviors induced by L-DOPA. The other, and neglected, aspect concerns the possible deleterious impact of the presence of L-DOPA inside 5-HT neurons on 5-HT neuronal function. Overall, the fact that 5-HT neurons release the newly synthesised DA from L-DOPA in multiple brain regions beyond the striatum gives new insight into the large impact of L-DOPA in the Parkinsonian brain and strengthens therapeutic perspectives targeting the 5-HT system to reduce both motor and non-motor complications of L-DOPA medication.</abstract>
</profileDesc>
</hal>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000608 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Corpus/biblio.hfd -nk 000608 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Hal |étape= Corpus |type= RBID |clé= Hal:hal-01178542 |texte= L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease. }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |